Skip to main content

Table 2 Current clinical trials in progress for targeted therapeutic options for gallbladder cancers (data from

From: Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico

Agent Target Regimen Phase Institution NCI Number
Cetuximab, Trastuzumab, Gefitinib, Lapatinib, Everolimus, Sorafenib, Crizotinib EGFR, HER2, mTOR, VEGF, ALK/ROS1, PDL-1 GEMOX + targeted therapy per proteomic/genetic profiling II Xinhua Hospital, Shanghai NCT02836847
Durvalumab PDL-1 Guadecitabine + Durvalumab I University of Southern California NCT03257761
Pazopanib cKIT, FGFR, VEGFR Gemcitabine + Pazobanib II Hellenic Cooperative Oncology Group NCT01855724
Pembrolizumab PD-1 Pembrolizumab + Cisplatin + Gemcitabine II European Organization for Research and Treatment of Cancer NCT03260712
Selumetinib MEK1, MEK2 Selumetinib + Cisplatin + Gemcitabine II University Health Network, Toronto NCT02151084
ADH-1 N-Cadherin ADH-1 + Cisplatin + Gemcitabine I University of Nebraska NCT01825603
Canlisib PI3K Copanlisib + Cisplatin + Gemcitabine II H. Lee Moffitt Cancer Center and Research Institute NCT02631590
Merestinib MET Merestinib + Cisplatin + Gemcitabine I Eli Lilly and Company NCT03027284
Regorafenib VEGF Regorafenib II H. Lee Moffitt Cancer Center and Research Institute NCT02115542